Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by barcodewhizon Feb 06, 2007 1:45pm
225 Views
Post# 12172677

RE: Delay-Delay-Delay....

RE: Delay-Delay-Delay.... I think you are missing the point. A Catalyst victory will result in a substantial amount of investment in Hemosol to bring it to commercial production. Catalyst has the access to capital to do this, AND attract alot of attention. PLI has to be an integral part of this renewal. Catalyst will want to ensure its future through some kind of substantial arrangement with Prometic. This could be as simple as a long term supply contract, or as complex as the formation of a JV company jointly owned by Prometic and Catalyst. Both GREAT for Prometic. At the very least, this situation will mean up front cash, or equivalent value for Prometic short term. Medium term, it will become a SUBSTANTIAL revenue stream for Prometic and a showcase for the technology. Ironically, this is what we hoped Hemosol would do, but the market never "bought it" because Hemosol couldnt raise capital as a fallen angel. CATALYST CAN... and as the likelihood of this all developing becomes clearer, the market WILL PAY ....all of which substantially increases the value of Prometic's franchise.
Bullboard Posts